To determine the sensitivity and accuracy of endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) for clarification of the nature of fluorodeoxyglucose-positron emission tomography ( 18 FDG) positive hilar and/or mediastinal lymph nodes in patients with (suspected) lung cancer. Methods: All consecutive patients who had undergone EBUS-TBNA alone for assessment of abnormal 18 FDG-uptake in hilar and/or mediastinal lymph nodes between January 2005 and August 2007 were reviewed. Results: One-hundred-nine patients underwent EBUS-TBNA of 127 positron emission tomography positive lymph nodes. Hilar (station 10 or 11) nodes (N1 or N3) were aspirated in 26 patients and mediastinal (stations 2, 4, 7) nodes (N2 or N3) in 90 patients. In 7 patients both hilar and mediastinal nodes were sampled. There were no procedure-related complications. Malignancy was detected in 77 (71%) cases. Thirty-two patients were tumor negative by EBUS-TBNA; subsequent surgical biopsy in 19 showed malignancy in 7. In four cases the false negative result was due to sampling error and in three cases due to detection error. In 13 cases surgical staging was not performed although long term follow-up in 3 showed no evidence of malignancy. The sensitivity and accuracy of EBUS-TBNA for malignancy in patients with reference pathology was 91% and 92%, respectively. The negative predictive value was 60%. If the 10 cases for which confirmatory surgical staging was not performed are
F luorodeoxyglucose-positron emission tomography (FDG-PET) is being increasingly used by oncologists, pulmonologists, and thoracic surgeons to evaluate lung masses, solitary pulmonary nodules and intrathoracic lymph nodes. As the availability of this technique becomes more widespread and the cost per examination decreases, it is likely that its position in the investigation algorithm will move forward, possibly even as a first line imaging investigation. Although undoubtedly useful, PET brings with it a new set of challenges, not least of which, is the necessity to be able to biopsy positive lymph nodes. A series of studies have shown that while PET has a high negative predictive value, it is neither sufficiently sensitive nor specific to differentiate benign from malignant intrathoracic lymph node involvement. 1, 2 Recent pooled data showed that the sensitivity and specificity of PET for predicting malignant involvement of mediastinal lymph nodes were 84% and 89%, respectively. 3 The acceptance that PET positive mediastinal lymph nodes equate to malignant involvement runs the risk of excluding patients from potentially curative surgery. As a result several national guideline groups advise that 18 FDG positive intrathoracic lymph nodes should be biopsied if it is likely that the result will alter clinical management. 4, 5 For many years surgical biopsy -principally cervical mediastinoscopy -has been regarded as the 'standard procedure' for sampling mediastinal lymph nodes. However, these techniques, require general anesthesia and may require an overnight stay. While the mediastinal lymph node stations can be accessed by one or more surgical approaches, access to hilar nodal stations can be difficult and may require thoracoscopy and on occasion a thoracotomy. In recent years there has been increasing interest in the use of minimally invasive methods for the evaluation of intrathoracic lymph nodes. One such technique, endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA), permits biopsy of both hilar and mediastinal lymph nodes. 6 -10 Our aim in this study was to assess the sensitivity and accuracy of EBUS-TBNA for clarification of the nature of 18 FDG PET positive hilar and/or mediastinal lymph nodes.
PATIENTS AND METHODS

Inclusion and Exclusion Criteria
We retrospectively reviewed the diagnostic performance of EBUS-TBNA for assessment of 18 FDG positive hilar or mediastinal lymph nodes. All consecutive patients, in each center, who had undergone EBUS-TBNA alone, for the purposes of diagnosis or staging (or both) between January 2005 and August 2007 were included. Patients who were undergoing EBUS-TBNA for the purposes of mediastinal restaging following induction chemotherapy were not eligible for this study. Each center gave approval for the conduct of the case note review.
Patients
The cohort consisted of 79 men and 30 women (age range 22-85 years-median 69 years) referred to Papworth Hospital, Cambridge, UK (n ϭ 43), Ghent University Hospital, Belgium (n ϭ 36) and Leiden University Medical Centre, The Netherlands (n ϭ 30). In 50 (46%) cases the patient was known to have lung cancer and in 59 (54%) cases the diagnosis was suspected. Of the 109 cases, abnormal FDG uptake was seen in solitary lymph nodes in 91 (83%) cases and in 2 or more nodes in 18 cases. In 30 (28%) of the 109 patients, the target lymph nodes were Ͻ10 mm in short axis.
18
FDG PET
All patients underwent either integrated 18 FDG PETcomputed tomography (CT) or 18 FDG-PET with side by side comparison with CT imaging. Although initial imaging was performed at several different referral centers in each country, 18 FDG-PET protocols were similar. Patients were fasted for 6 hours before the scan and glucose levels were confirmed to be Ͻ200 mg/dl. Image acquisition began exactly 60 minutes after an intravenous injection of 4 MBq/Kg FDG. Patients were scanned from midskull to midthigh and acquisition time was 3 minutes at each of 8 to 9 table positions. PET image data sets were reconstructed iteratively using a row action maximum likelihood algorithm. 18 FDG-PET was considered positive in hilar or mediastinal nodes if the PET report stated that there was hypermetabolic activity consistent with malignant disease (defined as standardized uptake value Ͼ2.5).
EBUS-TBNA
All EBUS examinations and TBNA procedures were performed under local anesthesia and moderate sedation using a linear array ultrasonic bronchoscope (BF-UC260F-OL8, Olympus Ltd., Tokyo Japan) as described previously. 11 A systematic assessment of all lymph node stations in both the hilar regions (stations 10R, 10L, 11R, and 11L) and the mediastinum (stations 2R, 2L, 4R, 4L, and 7) 12 was undertaken in addition to evaluation of the lymph node stations of interest (i.e., those that had shown 18 FDG uptake) ( Figure 1 ). Lymph nodes were sampled in the order N3 then N2 and then N1 to prevent up-staging in the event of any cross-contamination between samples. Smears of the aspirates obtained by EBUS-TBNA were either, air-dried, stained with DiffQuik™ and examined by ROSE (Leiden and Ghent) or collected into CytoLyt and processed in a cytopathology laboratory (Cambridge).
Surgical Staging Procedures
For patients who underwent mediastinoscopy, a standard cervical mediastinoscopy was performed under general anesthesia by a thoracic surgeon experienced in the technique. The standard of practice involved sampling of the lymph node stations: 2R, 2L, 4R, 4L, and 7. Video assisted thoracoscopic surgery (VATS) was performed in a lateral decubitus with single lung ventilation. One to three ports were used to permit access to lymph node stations 7, 8, and 9. For those undergoing thoracotomy, a standard posterolateral thoracotomy was performed with systematic hilar and mediastinal lymph node dissection. All mediastinal nodes that could be reached were actively sought and completely removed. For left sided tumors lymph node stations 2L, 4L, 5 to 9 were dissected and for right sided tumors lymph node stations 2R, 4R, 7 to 9 were dissected.
Statistical Analysis
For calculation of sensitivity and accuracy of EBUS-TBNA, only patients who had a confirmatory surgical staging investigation in the event of a negative for malignancy EBUS-TBNA were included. For statistical purposes it was assumed that positive for malignancy EBUS-TBNA results were true positive although it is recognized that rarely false positive results have been reported. 11 However, because it was not the normal clinical practice of the investigators to confirm positive EBUS-TBNA results by surgical biopsy the specificity of the technique was taken to be one. For the purposes of analysis a lymph node was regarded as positive for malignancy if it was shown to contain tumor as a result of either an EBUS-TBNA aspirate or by surgical biopsy. 
RESULTS
One hundred nine patients underwent EBUS evaluation of 127 lymph nodes. Details of lymph node stations biopsied are shown in Table 1 . Lymph node size ranged from 6 to 30 mm with a median size of 15 mm. The mean number of TBNA passes per node was 3.2 (range, 1-5).
Breakdown by nodal level biopsied showed that N1 nodes (lymph node stations 10 or 11) were targeted in 15 (14%) patients. Level N1 nodes were usually biopsied for diagnostic purposes rather than staging purposes. Level N2 nodes were biopsied in 80 (75%) patients and N3 nodes in 21 (19%) patients. N2 and N3 nodes were biopsied for either diagnostic and/or staging purposes. Of the N3 nodes assessed, 10 were contralateral mediastinal nodes (stations 2 or 4) and 11 were contralateral hilar nodes (stations 10 or 11). In 77 (71%) patients, a diagnosis of malignancy was obtained which obviated the need for further surgical biopsy (Figure 2) . TBNA results showed small cell lung cancer in 9 (12%) cases, adenocarcinoma in 25 (33%), squamous cell carcinoma in 20 (25%) and non small cell lung cancer (unspecified) in 23 (30%) cases. In 42 (55%) of the 77 cases EBUS-TBNA provided a primary tissue diagnosis in addition to giving staging information.
In 32 (29%) patients EBUS or EBUS-TBNA showed no evidence of malignancy ( Figure 2 ). In 19 patients, further surgical procedures were undertaken. A cervical mediastinoscopy or mediastinotomy was performed in 5 cases and VATS in 4 cases. In 10 patients a thoracotomy was performed following negative surgical staging procedures. These procedures confirmed a true negative EBUS-TBNA result in 12 of the 19 cases. All cases were shown to be T1-3 N0 non small cell lung cancer. The false positive FDG uptake in these lymph nodes was thought to be infection and/or inflammation. In seven cases, malignancy was identified by surgical staging or at thoracotomy indicating that the EBUS-TBNA result was a false negative. In four cases needle marks/ hematoma suggested that the correct lymph node had been sampled by EBUS-TBNA but surgical staging discovered malignancy i.e., these were due to sampling error. In all cases, subsequent biopsying revealed micrometastatic disease. In three cases nodes other than those sampled by EBUS were identified as being malignant. This was therefore due to detection error.
In the remaining 13 patients (9%) no further staging investigations were performed. In 3 cases, long term follow-up (12 months) and repeat CT indicated a benign etiology (infection) and these were deemed to be true negative cases for malignancy. In one case no further mediastinal staging was performed and the patient went on to have neo-adjuvant chemotherapy. Subsequent mediastinoscopy showed no evidence of mediastinal nodal involvement. The remaining nine patients were treated with palliative intent (chemotherapy, radiotherapy or active supportive care) for lung cancer on the grounds that they were too frail or ill to undergo further surgical staging procedures. Therefore, in these 10 cases it was not possible to accurately determine the true status of the EBUS-TBNA negative but PET positive nodes. Overall, for the 96 cases for which there was definitive reference pathology, the sensitivity of EBUS-TBNA on a per patient basis was 91% (95% CI 82-95) and diagnostic accuracy was 92%. Specificity was 100% (95% CI 73-100) and positive predictive value was 100% (95% CI 95-100). The negative predictive value was 60% (95% CI 36 -80). There was no significant difference in sensitivity for detection of malignancy between hilar (station 10 and 11) nodes (87%) and mediastinal (station 2, 4, and 7) nodes (92%). Comparison of data between the different centers showed very similar sensitivity figures: Cambridge 91%; Leiden 92%, and Ghent 89%. The overall prevalence of malignancy was 77%. If the 10 cases for which it was not possible to conclusively determine the true status of the EBUS negative but PET positive nodes are all assumed to be false negative EBUS-TBNA results, the sensitivity becomes 82% and accuracy 84%.
Analysis of PET positive lymph nodes that measured 10 mm or less showed that 33 lymph nodes were sampled from 30 patients. Nodal size ranged from 6 to 10 mm with a median of 8.6 mm. Fourteen patients had nodes that were shown to contain tumor at EBUS. In 16 cases, no tumor was found. Further surgical staging investigations or thoracotomy showed true negative results in six cases, false negative results in four cases and in the remaining six cases no standard procedure reference pathology was obtained. Analysis of the nodes on a per patient basis, for which there was reference pathology, showed a sensitivity of 77%.
In this series the use of EBUS-TBNA obviated the need for further surgical staging procedures in 71% of patients.
DISCUSSION
In this study we have shown that EBUS-TBNA is a sensitive and accurate technique for the characterization of PET positive hilar and mediastinal lymph nodes. The median size of nodes in this series was 15 mm and 25% were subcentimeter i.e., they were reported as normal on CT. Our findings show that it is feasible to use EBUS to identify and biopsy small FDG positive nodes under local anesthesia and moderate sedation as a day case. Similar results were observed in all the participating centers indicating that these results should be reproducible by the majority of reasonably experienced operators.
The increasing use of PET for assessment of lymph nodes brings with it the necessity to be able to biopsy positive findings as previous studies have shown that the sensitivity and specificity of PET is not sufficiently high to accurately determine whether lymph nodes are involved by tumor or not. 2 Until recently mediastinal lymph node sampling has relied on surgical biopsy techniques such as mediastinoscopy, anterior mediastinotomy or VATS, depending upon location. Such techniques entail a general anesthetic and often an in-patient stay and are relatively expensive. A standard cervical mediastinoscopy allows access to the upper mediastinum (lymph node stations 2, 4 and the upper/cranial portion of station 7) and a VATS procedure permits access to stations 7, 8, and 9. However, neither surgical staging procedure can access hilar nodal stations 10 and 11.
Historically, access to hilar nodes has often necessitated a thoracotomy and as a result is rarely performed routinely as a staging procedure. Furthermore, most practitioners of conventional nonultrasound guided TBNA have been reticent to biopsy these nodal stations due to the proximity of major vessels and the lung parenchyma. Therefore, contralateral N3 hilar nodes may not always be fully evaluated before thoracotomy. This has lead to futile thoracotomies being performed. In this study we have shown that using real-time EBUS guided-TBNA, FDG-positive hilar lymph node stations 10 and 11 (both N1 and N3) can be identified and sampled. The utility of EBUS-TBNA in this setting makes it a valuable tool for both diagnostic (N1) and diagnosis/staging (N2 and N3) purposes. Furthermore, sampling of hilar lymph nodes may, on occasion, help with assessment of the type of surgical resection required and determine whether sleeve resection, lobectomy or pneumonectomy is required.
Previous reports using EBUS-TBNA for biopsying PET positive mediastinal lymph nodes in lung cancer have shown similar results to our data. 10, 13 However, our multicenter data show similar results from each center demonstrating that this is a reliable technique with reproducible results that it should be possible to emulate in many centers with appropriate training.
The only other previous studies describing real-time ultrasound guided biopsy of PET positive mediastinal lymph nodes concerned EUS-FNA. 14, 15 The access afforded by EBUS is complimentary to that accessible by EUS. While EBUS allows access to paratracheal, subcarinal, and hilar nodes, EUS permits access to paraoesophageal regions. The combination of EBUS and EUS allows access to all mediastinal lymph node stations except stations 5 and 6 and offers the prospect of even greater sensitivity and accuracy for mediastinal staging. 16 -18 Although EBUS-TBNA and EUS-FNA have been shown in a number of studies to have high sensitivity and accuracy for the detection of metastatic disease, the concern is often raised that fine needle aspiration sampling may miss small metastatic tumor deposits in some cases. We examined the reasons for false negative results (7 cases). We concluded that in four cases it was due to sampling error (i.e., the appropriate lymph node was identified but tumor was not detected on sampling) and in three cases due to detection error (the PET positive node was not identified correctly). Sampling error will always be a potential problem if only a small amount of tumor is present within a node but the risk of a false negative result can be ameliorated by multiple passes to different parts of the node (average 3.2 passes per node in this study). A recent study by Seok Lee et al. 19 showed that maximum diagnostic values were achieved with three aspirations. Detection error can be minimized with careful examination of all lymph node stations regardless of FDG uptake. It is known that low volume disease within a lymph node may give a false negative PET result. Herth et al. 20 have recently reported that up to 10% of patients staged T1N0 by CT-PET have unexpected hilar or mediastinal metastases. Therefore, it is our practice to perform confirmatory surgical staging of EBUS-TBNA negative for malignancy nodes if clinical suspicion exists and it will alter management.
We do recognize several limitations to this study. The analysis was performed retrospectively although data was collected prospectively. To avoid selection bias we assessed all consecutive patients who were referred for EBUS at each center for evaluation of PET positive mediastinal lymph nodes. Identification of all appropriate cases was facilitated by access to the prospective databases that each operator maintains of all their cases. We noted that the majority of paratracheal nodes sampled were right sided. In this series this finding is explained by the fact that all three participating centers also routinely use EUS which is often used in preference to EBUS for sampling of left paratracheal nodes. Had EUS-FNA not been available, the percentage of left paratracheal nodes sampled by EBUS-TBNA would likely have been higher. With regard to the analysis of results tumor positive EBUS-TBNA results were not surgically verified as this was not felt to be ethically acceptable and it was assumed that there were no false positive results although it is recognized that they can occur. 21 As the use of PET becomes more prevalent, the ability to investigate the mediastinum using a minimally invasive day case based procedure rather than a surgical approach requiring in patient care and general anesthesia may offer a financial saving for health care systems. In this study we found that the use of EBUS-TBNA obviated the need for surgical staging procedures in 71% of cases. Future studies should concentrate on the health economics and cost effectiveness of such an approach. In addition to staging, these technologies often allow primary diagnosis to be made at the same time. In this series EBUS-TBNA provided a primary tissue diagnosis in addition to giving staging information in 55% of cases. In conclusion, EBUS-TBNA offers clinicians a sensitive, safe and minimally invasive strategy for the assessment of FDG avid hilar and mediastinal lymph nodes. As PET becomes more widespread and commonplace within investigation algorithms, the necessity to be able to biopsy intrathoracic lymph nodes quickly and efficiently will likely lead to techniques such as EBUS and EUS becoming the new first line investigation. However, the relatively low negative predictive value indicates that negative results should be confirmed by surgical biopsy.
